2. Search Result
Search Result
Pathways Recommended: PI3K/Akt/mTOR
Results for "

PI3K (p85)

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

3

Peptides

1

Recombinant Proteins

4

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0175
    740 Y-P
    170+ Cited Publications

    740YPDGFR; PDGFR 740Y-P

    		 PI3K Autophagy Cancer
    740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
    740 Y-P
  • HY-121435
    K-8012

    		RAR/RXR PI3K Akt Apoptosis Cancer
    K-8012, a sulindac (HY-B0008) analog, is a potent antagonist of RXRa. The IC50 value for K-8012 to inhibit 9-cis-RA-induced Gal4-RXRa-LBD trans-activation were about 9.2 μM. K-8012 exerts improved anticancer activity over sulindac in a RXRa-dependent manner. K-8012 exhibits activity in inhibiting the tRXRa-mediated PI3K/AKT signaling pathway. K-8012 induces apoptosis and inhibits AKT activation by preventing tRXRa from binding to p85a .
    K-8012
  • HY-171777
    Erufosine

    ErPC3; Erucylphosphohomocholine

    		 PI3K Akt Ras Raf p38 MAPK Cancer
    Erufosine is an inhibitor of PI3K/Akt and Ras/Raf/MAPK signaling pathways. Erufosine inhibits the activity of breast cancer cell lines MCF-7 and MDA-MB 231 (IC50: 40.95/40.8 μM). Erufosine reduces the phosphorylation of PI3K (p85), Akt (PKB), and cRaf. Erufosine can be used in the study of breast cancer and myeloid leukemia .
    Erufosine
  • HY-P10090
    Apoptin-derived peptide

    		Akt PI3K Apoptosis Cancer
    Apoptin-derived peptide is an antitumor polypeptide with cytotoxicity. Apoptin-derived peptide promotes apoptosis and necrosis of gastric cancer (GC) cells by regulating PI3K/AKT/ARNT signaling. Apoptin-derived peptide inhibited the invasion and migration of cancer cells, and inhibited the expression and phosphorylation of the subunit p85 of PI3K, which further inhibited the PI3K/AKT pathway involved in the development of gastric cancer .
    Apoptin-derived peptide
  • HY-P0175A
    740 Y-P TFA

    740YPDGFR TFA; PDGFR 740Y-P TFA

    		 PI3K Autophagy Cancer
    740 Y-P TFA is a potent and cell-permeable PI3K activator. 740 Y-P TFA readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
    740 Y-P TFA
  • HY-160418
    PI3K-IN-51

    		PI3K Cancer
    PI3K-IN-51 is a PI3K inhibitor with IC50 values <500 nM for p120γ and p110δ/p85α (WO2016204429A1; Example 10) .
    PI3K-IN-51
  • HY-157287
    (S)-Phe-A110/B319

    		Others Inflammation/Immunology
    (S)-Phe-A110/B319 is a selective binde that has 20-fold higher affinity towards the H1047R mutant of p110α in the p110α/p85α PI3K complex .
    (S)-Phe-A110/B319
  • HY-157288
    (R)-Phe-A110/B319

    		Biochemical Assay Reagents Metabolic Disease
    (R)-Phe-A110/B319, a hapten, is a selective binder to tumor-associated antigens. (R)-Phe-A110/B319 has a 20-fold higher affinity towards the H1047R mutant of p110α in the p110α/p85α PI3K complex. (R)-Phe-A110/B319 can be used for the research of conditional chimeric antigen receptor T (CAR-T) cell activation and tumor targeting .
    (R)-Phe-A110/B319

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: